Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Updated analysis of the observational GioTag study

Maximilian J. Hochmair; Alessandro Morabito; Desiree Hao; Cheng Ta Yang; Ross A. Soo; James C.H. Yang; Rasim Gucalp; Balazs Halmos; Lara Wang; Angela Märten; Tanja Cufer

doi:10.2217/fon-2019-0346

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Updated analysis of the observational GioTag study

Maximilian J. Hochmair^*, Alessandro Morabito, Desiree Hao, Cheng Ta Yang, Ross A. Soo, James C.H. Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Angela Märten, Tanja Cufer

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

71 Scopus citations

Abstract

Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. Trial registration number: NCT0337077.

Original language	English
Pages (from-to)	2905-2914
Number of pages	10
Journal	Future Oncology
Volume	15
Issue number	25
DOIs	https://doi.org/10.2217/fon-2019-0346
State	Published - 2019
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2019 Maximilian J Hochmair.

Keywords

NSCLC
T790M
afatinib
osimertinib
sequential

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fon-2019-0346

Cite this

Hochmair, M. J., Morabito, A., Hao, D., Yang, C. T., Soo, R. A., Yang, J. C. H., Gucalp, R., Halmos, B., Wang, L., Märten, A., & Cufer, T. (2019). Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Updated analysis of the observational GioTag study. Future Oncology, 15(25), 2905-2914. https://doi.org/10.2217/fon-2019-0346

@article{6bc1e5a852e648c796766a6b917e6f2b,

title = "Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Updated analysis of the observational GioTag study",

abstract = "Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. Trial registration number: NCT0337077.",

keywords = "NSCLC, T790M, afatinib, osimertinib, sequential",

author = "Hochmair, {Maximilian J.} and Alessandro Morabito and Desiree Hao and Yang, {Cheng Ta} and Soo, {Ross A.} and Yang, {James C.H.} and Rasim Gucalp and Balazs Halmos and Lara Wang and Angela M{\"a}rten and Tanja Cufer",

note = "Publisher Copyright: {\textcopyright} 2019 Maximilian J Hochmair.",

year = "2019",

doi = "10.2217/fon-2019-0346",

language = "英语",

volume = "15",

pages = "2905--2914",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor and Francis Ltd.",

number = "25",

}

TY - JOUR

T1 - Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer

T2 - Updated analysis of the observational GioTag study

AU - Hochmair, Maximilian J.

AU - Morabito, Alessandro

AU - Hao, Desiree

AU - Yang, Cheng Ta

AU - Soo, Ross A.

AU - Yang, James C.H.

AU - Gucalp, Rasim

AU - Halmos, Balazs

AU - Wang, Lara

AU - Märten, Angela

AU - Cufer, Tanja

PY - 2019

Y1 - 2019

N2 - Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. Trial registration number: NCT0337077.

AB - Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. Trial registration number: NCT0337077.

KW - NSCLC

KW - T790M

KW - afatinib

KW - osimertinib

KW - sequential

UR - http://www.scopus.com/inward/record.url?scp=85071633846&partnerID=8YFLogxK

U2 - 10.2217/fon-2019-0346

DO - 10.2217/fon-2019-0346

M3 - 文献综述

C2 - 31370698

AN - SCOPUS:85071633846

SN - 1479-6694

VL - 15

SP - 2905

EP - 2914

JO - Future Oncology

JF - Future Oncology

IS - 25

ER -

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Updated analysis of the observational GioTag study

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this